Skip to content
OpenCapital
Get started

Nektar Therapeutics NKTR Debt issuance costs and discount amortization

Debt issuance costs and discount amortization at other companies

Tidewater logo
TidewaterTDW
$848K-43.5%
MH
McGraw Hill, Inc.MH
$3.05M-46.7%
Braze, Inc. logo
Braze, Inc.BRZE
-$78K+80.5%
Under Armour logo
Under ArmourUAA
$713K+15.7%
Asana logo
AsanaASAN
$30K0.0%
Shake Shack logo
Shake ShackSHAK
$26K-21.2%

Other financials

Income statement

See full
Revenue$10.9M+3.8%
Gross profit$21.8M+2.9%
Operating income-$39.1M+12.3%
Net income-$44.9M+11.7%
EPS (diluted)-$1.82+49.7%

Balance sheet

See full
Cash & equivalents$5.7M-20.0%
Total debt$83.2M-17.1%
Total equity$576.2M+4,094%
Total assets$763.3M+198%

Cash flow

See full
Operating cash flow-$44.3M+9.7%
CapEx$18.0K+800%
Free cash flow-$44.3M+9.7%

Valuation

See full
Market cap$2.19B+1,531%

Profitability

See full
Gross margin100%+31.2pp
Operating margin-242%—
Net margin-284.2%+937pp
FCF margin-366.6%+1,421pp

Returns & leverage

See full
Return on equity-53.6%-22.6pp
Debt / equity0.1×-7.2×
Current ratio10.2×+7.0×

Where this comes from

Reported directly by Nektar Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:AmortizationOfDebtDiscountPremium.

The official record: Nektar Therapeutics’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about Nektar Therapeutics's debt issuance costs and discount amortization.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Nektar Therapeutics's debt issuance costs and discount amortization?
Nektar Therapeutics (NKTR) reported debt issuance costs and discount amortization of -$1.66M in Q1 2026.
How has Nektar Therapeutics's debt issuance costs and discount amortization changed year-over-year?
Nektar Therapeutics's debt issuance costs and discount amortization decreased by 25.6% year-over-year, from -$1.32M to -$1.66M.
What is the long-term trend for Nektar Therapeutics's debt issuance costs and discount amortization?
Over 2 years (2023 to 2025), Nektar Therapeutics's debt issuance costs and discount amortization has grown at a -39.1% compound annual growth rate (CAGR), from -$14.86M to -$5.51M.